Navigation Links
Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms
Date:7/27/2011

COLORADO SPRINGS, Colo., July 27, 2011 /PRNewswire/ -- Stryker Neurovascular, a division of Stryker Corporation, today announced the results of its Matrix and Platinum Science (MAPS) Trial during the Society of NeuroInterventional Surgery (SNIS) 8th Annual Meeting in Colorado Springs. The MAPS Trial establishes a new standard for the measurement of aneurysm treatment success, target aneurysm recurrence rate (TAR)*, and proves that coiling is an excellent treatment for both ruptured and unruptured aneurysms.

Begun in 2007, the MAPS trial is the largest, most rigorous randomized controlled study to-date on the clinical effectiveness of coils for treating both ruptured and unruptured aneurysms, which are estimated to affect approximately 5% of the population. Designed and led by Principal Investigators S. Claiborne Johnston, M.D., Ph.D., Cameron McDougall, M.D., and Anil Gholkar, O.B.E., M.B.B.S., the trial examined 626 patients worldwide with a single aneurysm, 4-20mm in size, treated with Matrix(2)® Detachable Coils or GDC® Detachable Coils.

Implanted in more than 250,000 patients worldwide, GDC Detachable Coils are made of very soft platinum wire and were the first coils cleared by the FDA for the minimally invasive treatment of brain aneurysms in 1995. Cleared in 2002, Matrix(2) Detachable Coils incorporate a PGLA polymer on the outside of a traditional platinum coil that is designed to degrade over time and promote rapid tissue development within the aneurysm.

"While the neurovascular specialty commonly measures aneurysm treatment success with angiographic images, we believe success should be more closely aligned with patients' clinical outcomes," said Mark Paul, president of Stryker Neurovascular. "The MAPS Trial demonstrates the validity of TAR as a clinical endpoint and proves aneurysm coiling is a very effective therapy with excellent clinical outcomes."

In the trial, 96% of patients with unruptured aneurysms and 90% of patients with acutely ruptured aneurysms were alive and free of disability out to 15 months after treatment. Trial results also demonstrate that, overall, Matrix(2) Detachable Coils are as effective as GDC Detachable Coils (TAR rates of 13.3% vs. 14.6%, respectively).  In aneurysms with good occlusion (minimal blood flow entering the aneurysm) immediately post procedure, Matrix(2) Detachable Coils demonstrate a statistically significant, superior long-term TAR rate of 2.7% compared to GDC Detachable Coils (9.6%).

"The MAPS Trial shows that the field of neurointervention is now mature enough to successfully carry out a randomized, prospective trial that is rigorously overseen, assesses the performance of contemporary technology and is applicable worldwide," said Cameron McDougall, M.D., the current president of SNIS. ** "While not comparing clipping to coiling, the trial shows better endovascular results than previous benchmark studies, specifically ISAT and ISUIA***. In addition, the trial's clinical endpoint has been demonstrated to be clinically relevant and correlate with immediate post-treatment angiogram, making it reliable and easily adopted by future studies to ensure a consistent measure of treatment success."

"Stryker is very encouraged by the results of the MAPS Trial, and we believe that it has the potential to influence the design of future studies and spur the advancement of new, innovative technologies that can enhance the clinical outcomes of patients with aneurysms in the future," Mark Paul continued.

*Target aneurysm recurrence is defined as aneurysm recurrence evidenced by a clinically relevant event of aneurysm bleeding/rebleeding, aneurysm reintervention or death from an unknown cause.

**Cameron McDougall, M.D., did not have any financial compensation for his participation in the trial nor does he have any financial interest in the products.

***ISAT refers to the International Subarachnoid Aneurysm Trial, and ISUIA refers to the International Study of Unruptured Intracranial Aneurysms.

About Stryker

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

About the Society of NeuroInterventional Surgery

The Society of NeuroInterventional Surgery (SNIS) is represented by physicians who specialize in minimally invasive techniques to treat neurovascular conditions, including stroke, aneurysms, carotid stenosis and spinal abnormalities.  Drawing on diverse backgrounds and expertise including interventional neuroradiology, neurosurgery and neurology, these physicians are continuing to forge new pathways in the development of the distinct specialty of neurointervention.  Over the past two decades, practitioners of this field have paved the way for the scientific research and study that has resulted in new technology and revolutionary treatment approaches that have transformed the neurosciences.  In keeping with the mission of SNIS, the society remains committed to working in partnership to advance the science and medical environment that will result in enhanced quality of care for patients across the globe.

Media Contact

Russell Weigandt
Kwittken & Company
646-747-7163
stryker@kwitco.com


'/>"/>
SOURCE Stryker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
7. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
10. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
11. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):